Activin A and follistatin in patients with nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective There are limited data on the role of activin A and its binding protein, follistatin, in nonalcoholic fatty liver disease (NAFLD). The main aim was the evaluation of serum activin A and follistatin levels in patients with biopsy-proven NAFLD vs. controls. Methods This was a case-control study. Fifteen patients with nonalcoholic simple steatosis (SS), 16 with steatohepatitis (NASH), and 52 (24 lean and 28 obese) controls were recruited. Activin A and follistatin were measured using ELISA. Results Activin A levels showed a trend towards progressive increase (p=0.010) from the controls (lean: 356±25, 95% CI 305–408; obese 360±20, 95% CI 320–401 pg/ml) to SS (407±28, 95% CI 347–466 pg/ml) and NASH patients (514±70 95% CI 364–664 pg/ml); this association became non-significant after adjusting for adiposity. Follistatin was not different between groups (lean controls: 1.11±0.08, 95% CI 0.95–1.28; obese controls: 1.00±0.07, 95% CI 0.86–1.14; SS: 0.86±0.07, 95% CI 0.70–1.02; NASH: 1.14±0.09, 95% CI 0.90–1.37 ng/ml; p=0.13). Within the NAFLD group of patients, follistatin was associated with NASH independently from activin A, gender and age, a relationship however likely reflecting the effect of adiposity. Conclusions Activin A is higher in patients with NASH than both lean and obese controls. Future clinical studies are needed to confirm and expand these findings, whereas mechanistic studies exploring underlying mechanisms are also warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Leptin in nonalcoholic fatty liver disease: A narrative review
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.012 · Cited by 235 · cited 2×
“[18] Polyzos SA, Kountouras J, Mantzoros CS.”
BackgroundSelf-citationIrisin in patients with nonalcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Anastasilakis, A. D., Geladari, E. V., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.013 · Cited by 215
Self-citationIrisin: A renaissance in metabolism?
Polyzos, S. A., Kountouras, J., Shields, K., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.04.008 · Cited by 131
Self-citationCirculating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio
Hansen, J. S., Rutti, S., Arous, C., Clemmesen, J. O., Secher, N. H., Drescher, A., Gonelle-Gispert, C., Halban, P. A., Pedersen, B. K., Weigert, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3668 · Cited by 125
A complex role of activin A in non-alcoholic fatty liver disease
Yndestad, A., Haukeland, J. W., Dahl, T. B., Bjøro, K., Gladhaug, I. P., Berge, C., Damås, J. K., Haaland, T., Løberg, E. M., Linnestad, P., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.318 · Cited by 75 · cited 7×
“Moreover, it inhibits the proliferation and induces apoptosis of hepatocytes, contributing to the termination of liver regeneration; the proliferation of liver progenitor cells and their mediated liver regeneration are controlled by activin A [10,11].”
BackgroundResultInfluential
Cited by
Hepatic macrophages: Key players in the development and progression of liver fibrosis
Cheng, D., Chai, J., Wang, H., Fu, L., Peng, S., & Ni, X. (2021) · Liver International · doi:10.1111/liv.14940 · Cited by 188
Perakakis, N., Polyzos, S. A., Yazdani, A., Sala-Vila, A., Kountouras, J., Anastasilakis, A. D., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154005 · Cited by 137
Self-citationRole of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Perakakis, N., Mougios, V., Fatouros, I., Siopi, A., Draganidis, D., Peradze, N., Ghaly, W., & Mantzoros, C. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01056 · Cited by 52
Self-citation
Metadata
- Authors
- Polyzos, S. A., Kountouras, J., Anastasilakis, A. D., Triantafyllou, G. Α., & Mantzoros, C. S.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 65
- Issue
- 10
- Pages
- 1550-1558
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2500667229
- Cited by
- 36
- References
- 6
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activin A and follistatin in patients with nonalcoholic fatty liver disease. https://app.cochat.ai/papers/10.1016/j.metabol.2016.07.009
- The paper
- Polyzos, S. A., Kountouras, J., Anastasilakis, A. D., Triantafyllou, G. Α., & Mantzoros, C. S. (2016). Activin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism. https://doi.org/10.1016/j.metabol.2016.07.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.